Literature DB >> 3838488

Determination of the muscarinic receptor subtype mediating vasodilatation.

R M Eglen, R L Whiting.   

Abstract

The muscarinic receptor mediating vasodilatation of the rabbit aorta and dog femoral artery has been assessed using muscarinic antagonists. With the exception of pirenzepine, the antagonist affinities were similar to those reported for the ileal receptors and dissimilar to those reported for the atrial receptors. Pirenzepine exhibited an affinity (7.54) intermediate between that reported for the CNS receptors (8.4) and that reported for the ileal receptors (6.77). This value for pirenzepine was confirmed using acetylcholine as the agonist and using the dog femoral artery as the vascular tissue. It is concluded that the muscarinic receptor profile mediating vasodilatation is not easily accommodated into the current receptor classification.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838488      PMCID: PMC1987201     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Comparison of the autonomic effects of some currently-used neuromuscular blocking agents [proceedings].

Authors:  R J Marshall; J A Ojewole
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

2.  Antagonist discrimination between ganglionic and ileal muscarinic receptors.

Authors:  D A Brown; A Forward; S Marsh
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

3.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization.

Authors:  R Hammer; A Giachetti
Journal:  Life Sci       Date:  1982-12-27       Impact factor: 5.037

4.  Three types of muscarinic receptors? [proceedings].

Authors:  R B Barlow; K N Burston; A Vis
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

5.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 1: Antimuscarinic and spasmolytic effects.

Authors:  J M Zwagemakers; V Claassen
Journal:  Arzneimittelforschung       Date:  1980

7.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

  7 in total
  7 in total

Review 1.  Proposed new lymphology combined with lymphatic physiology, innate immunology, and oncology.

Authors:  Toshio Ohhashi; Yoshiko Kawai
Journal:  J Physiol Sci       Date:  2014-11-07       Impact factor: 2.781

2.  Proceedings of the British Pharmacological Society. 9th-11th September 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

3.  Radioligand binding to muscarinic receptors of bovine aortic endothelial cells.

Authors:  F Brunner; W R Kukovetz
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

4.  Heterogeneity of muscarinic receptors in lamb isolated coronary resistance arteries.

Authors:  U Simonsen; D Prieto; L Rivera; M Hernández; M J Mulvany; A García-Sacristán
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

5.  Release of endothelium-derived hyperpolarizing factor (EDHF) by M3 receptor stimulation in guinea-pig coronary artery.

Authors:  A K Hammarström; H C Parkington; H A Coleman
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

6.  The interaction of methoctramine and himbacine at atrial, smooth muscle and endothelial muscarinic receptors in vitro.

Authors:  R M Eglen; W W Montgomery; I A Dainty; L K Dubuque; R L Whiting
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

7.  Interaction of some muscarinic agonists and antagonists at the prejunctional muscarinic receptor in the rabbit ear artery preparation.

Authors:  L K Choo; F Mitchelson; Y M Vong
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.